29 March, 2023
barnaclinic+ incorporates early diagnosis programmes for prostate and breast cancer
Cancer is one of the most common diseases. The great advances in medicine in recent years have made it possible to improve the survival rate of this disease. However, it is still the leading cause of death in the world today. One of the decisive factors for a good prognosis is the stage of development of the tumour. Many cases can be cured if detected early and treated effectively. For this reason, early cancer diagnosis programmes are a very important tool. barnaclinic+ currently has a new Medical Screening unit, which offers early diagnosis programmes for colon and rectal cancer, lung cancer, skin cancer and melanoma. This offer is now being extended to include the early diagnosis of prostate cancer, the most common tumour among men, and breast cancer, the most common among women. While the programmes themselves already existed, an updated portfolio of services has been defined. In these new programmes, as in those that already existed, patients will receive care from the best specialists in these areas, who have proven experience and are international benchmarks. Likewise, the most advanced and precise technology is available, which allows the identification of tumour lesions in their earliest stages.
16 November, 2022
HER2DX, one of the best inventions of 2022 according to TIME magazine
Every year, TIME draws up a list of the best inventions, those that according to the prestigious magazine “make the world better, smarter and even more fun”. In the 2022 ranking, they have included, in the “Medical Care” category, HER2DX, a genomic test that predicts survival and the possibility of responding to treatments in HER2-positive breast cancer patients in their earliest stages, the first genomic test created worldwide for this disease.
28 January, 2022
A new genomic test allows personalising the treatment of HER2+ breast cancer
Cancer is a very heterogeneous disease and that is why research is being carried out to develop treatments that are adapted to the characteristics of each subtype. But then there is the challenge of identifying which patients benefit most from each treatment. With this in mind, HER2DX has been created, a genomic test that predicts survival and the possibility of responding to treatment in HER2-positive breast cancer patients in their earliest stages. This tool is the first genomic test created worldwide for this disease and researchers from the Clínic – IDIBAPS – UB, the Vall d’Hebron Instituto de Oncología, the Università di Padova (Italia) and REVEAL GENOMICS.
